.png?width=500&height=162&name=Generis%20Logo%20(2).png "Generis Logo (2)")
Recent Posts
Biopharma M&A activity has already been big news in 2018. On January 22, it was reported that Celgene had bought the...
Last year, at the American Biomanufacturing Summit, we sat down with some thought leaders from MedImmune, AstraZeneca,...
Last year, at the American Biomanufacturing Summit, we sat down with some of our thought leaders to ask them where they...
In your experience, what has the outcome been like when an organization has taken the time to improve its’ single-use...
Many biopharmaceutical manufacturers are Implementing single-use containment and transfer of media and buffer materials...
Protein-based therapeutics, specifically monoclonal antibodies (mAbs), have become the focus of pharmaceutical R&D over...
This article first appeared in BioPharm International, October 1, Caroline Hroncich
Single use powder containment practices are still in their infancy but keeping your product from cross contamination...
You know that tomorrow’s medicine is personalized. With more than 8,100 active cell therapy studies and 1,300 active...
At the American Biomanufacturing Summit last May we had the opportunity to sit down with one of our key speakers,...